Status:
UNKNOWN
Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Type 1 Diabetes
Autoimmune Diseases
Eligibility:
All Genders
6+ years
Brief Summary
This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children a...
Eligibility Criteria
Inclusion
- Patients with type 1 diabetes diagnosed with the following criteria: (i) Classic symptoms of diabetes or hyperglycemic crisis, with plasma glucose concentration ≥11.1 mmol/L (200 mg/dl), or (ii) fasting plasma glucose ≥7.0 mmol/l (≥126 mg/dl) ; and (iii) presence of diabetes associated autoantibodies : ICA, GAD, IA2, IAA and/or ZnT8
- age \< 18 years old at type 1 diabetes diagnostic
- type 1 diabetes diagnosed between 2014-01-01 and 2021-02-01
Exclusion
- type 1 diabetes diagnostic not certain
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04789993
Start Date
March 15 2021
End Date
April 30 2021
Last Update
March 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital d'Enfants de Brabois
Vandœuvre-lès-Nancy, Lorraine, France, 54500